Senores Pharmaceuticals Limited (NSE:SENORES)

Market Cap	60.58B +153.7%
Revenue (ttm)	6.33B +58.9%
Net Income	1.16B +98.7%
EPS	26.39 +63.9%
Shares Out	46.05M
PE Ratio	49.84
Forward PE	41.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,598
Open	1,315.40
Previous Close	1,315.40
Day's Range	1,305.00 - 1,339.90
52-Week Range	513.00 - 1,360.00
Beta	n/a
Analysts	Strong Buy
Price Target	1,174.25 (-10.7%)
Earnings Date	Jul 24, 2026

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited develops, manufactures, sells, and trades in pharmaceutical and allied products in India, the United States, the United Kingdom, Canada, and internationally. It offers pharmaceutical solutions, such as analgesic/antipyretic, anesthetics and allied products, antibacterial/antibiotic, antiviral, antifungal, antioxidants, antineoplastic, blood line, cardiovascular, neurology, antacid, and vitamin and mineral preparation solutions; and analgesic/anti-inflammatory/antipyretic, anti-diabetic, antimalarial, neutral supp...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2017
• Employees: 194
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SENORES

Financial Performance

In fiscal year 2026, Senores Pharmaceuticals's revenue was 6.33 billion, an increase of 58.85% compared to the previous year's 3.98 billion. Earnings were 1.16 billion, an increase of 98.74%.

Analyst Summary

According to 4 analysts, the average rating for SENORES stock is "Strong Buy." The 12-month stock price target is ₹1,174, which is a decrease of -10.70% from the latest price.

Price Target

₹1,174

(-10.70% downside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 19, 2026

Data Sources Report a data error